Previous Close | 254.76 |
Open | 259.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 259.00 - 259.00 |
52 Week Range | 243.42 - 354.00 |
Volume | |
Avg. Volume | 213 |
Market Cap | 188.574B |
Beta (5Y Monthly) | 0.15 |
PE Ratio (TTM) | 16.63 |
EPS (TTM) | 15.57 |
Earnings Date | Jul 25, 2024 |
Forward Dividend & Yield | 10.86 (4.19%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | N/A |
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Q1 2024 Sarepta Therapeutics Inc Earnings Call
CQDM is proud to announce the funding of a collaborative research project to identify biomarkers and therapeutic solutions for diabetic kidney disease (DKD), one of the leading causes of kidney failure. This project, with a total value of over $9.4M, is made possible thanks to a $1.5M grant from the Quebec government (MEIE) awarded by CQDM, as well as a $2.4M financial contribution from Hoffmann-La Roche Limited (Roche) and another $2.8M from the Jewish General Hospital Foundation, and nearly $2